Journal of Psoriasis and Psoriatic Arthritis最新文献

{"title":"Associations Between Clinical Characteristics and Magnetic Resonance Imaging of the Sacroiliac Joints and Spine: Exploratory Analysis of the Phase 4, Randomized, Placebo-Controlled STAR Study.","authors":"Xenofon Baraliakos, Paul Bird, Atul Deodhar, Dafna D Gladman, Philip S Helliwell, Denis Poddubnyy, Arthur Kavanaugh, Mikkel Østergaard, Enrique R Soriano, Lai-Shan Tam, Soumya D Chakravarty, Evan Leibowitz, Cinty Gong, Oyediran Adelakun, Stephen Xu, Thomas Fuerst, Nadeem Saeed, Robert Landewé, Philip J Mease","doi":"10.1177/24755303261494534","DOIUrl":"10.1177/24755303261494534","url":null,"abstract":"<p><strong>Objective: </strong>To compare demographic and clinical characteristics of patients who did and did not meet the magnetic resonance imaging (MRI) axial inflammation eligibility criteria for the STAR study.</p><p><strong>Methods: </strong>STAR is a phase 4, randomized, placebo-controlled trial of guselkumab, a selective interleukin-23p19-subunit inhibitor, in participants with active PsA and MRI-confirmed axial inflammation. Axial involvement was defined as having a BASDAI score ≥4, spinal pain (BASDAI Question 2≥4, and MRI-confirmed axial inflammation (centrally read): Spondyloarthritis Research Consortium of Canada (SPARCC) score ≥3 for the sacroiliac joints (SIJ) or spine. Utilizing data from patients screened for STAR, this exploratory post hoc analysis compared demographic and disease characteristics for patients with both positive and both negative MRI scores (SIJ+/Spine+ vs SIJ-/Spine-).</p><p><strong>Results: </strong>Among 487 screened patients in STAR, 433 had available MRI scores for both SIJ and Spine (SIJ+/Spine+: 65 [15%]; SIJ-/Spine-: 257 [59%]). The SIJ+/Spine+ subgroup had a higher mean CRP level (2.3 vs 1.4 mg/dL), higher mean spinal pain score (7.8 vs 7.3), and lower mean swollen (6.6 vs 8.1) and tender (11.1 vs 15.6) joint counts relative to the SIJ-/Spine- subgroup (all nominal <i>P</i> < 0.05). SIJ+/Spine+ patients were also significantly more likely to be male (Odds ratio [95% confidence intervals]: 3.96 [2.14, 7.34]) and numerically more likely to have a history of inflammatory back pain, while the presence of palmoplantar psoriasis was numerically less common than in SIJ-/Spine- patients.</p><p><strong>Conclusions: </strong>Among patients with active PsA, male sex and higher CRP levels were significantly associated with MRI-confirmed SIJ and spinal inflammation.</p><p><strong>Registration: </strong>ClinicalTrials.gov: NCT04929210.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261494534"},"PeriodicalIF":0.0,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13677986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials.","authors":"Iain B McInnes, Linda Stein Gold, Robert Bissonnette, Mark G Lebwohl, Ofelia Reyes-Servin, Joseph Cafone, Ya-Wen Yang, Soumya D Chakravarty, Charles Iaconangelo, Shu Li, Tasneam Shagroni, Karissa Lozenski, April W Armstrong, Joseph F Merola","doi":"10.1177/24755303261494526","DOIUrl":"10.1177/24755303261494526","url":null,"abstract":"<p><strong>Background: </strong>Icotrokinra, a targeted oral peptide that precisely blocks the interleukin-23 receptor, is approved to treat adult and pediatric (≥12 years, ≥40 kg) patients with moderate-to-severe plaque psoriasis (PsO).</p><p><strong>Objective: </strong>Assess psoriatic arthritis (PsA)-specific outcomes through Week (W) 16 in a subgroup of phase-3 study participants with moderate-to-severe plaque PsO and self-reported medical history of PsA (PsO+PsA).</p><p><strong>Methods: </strong>Post-hoc analyses pooled data from ICONIC-LEAD and ICONIC-ADVANCE 1 and 2 among PsO+PsA participants randomized to once-daily icotrokinra 200 mg or placebo through W16. PsA-specific outcomes included mean change from baseline and ≥50% improvement in Patient's Global Assessment (PtGA) of PsA disease activity and Patient's Assessment of PsA Pain, and percent change from baseline in modified Nail Psoriasis Severity Index (mNAPSI). <i>P</i> values are nominal.</p><p><strong>Results: </strong>Analyses included 216 participants (149 icotrokinra, 67 placebo). At W8, icotrokinra-treated participants reported greater improvements vs placebo in PtGA of PsA disease activity (-18.5 vs -4.8; <i>P</i> < 0.001) and PsA Pain (-17.1 vs -4.6; <i>P</i> < 0.001), with improvement sustained at W16 (-19.2 vs -0.8; <i>P</i> < 0.001; -19.5 vs -7.8; <i>P</i> = 0.003). At W16, greater proportions of icotrokinra-treated vs placebo-treated participants achieved ≥50% improvement in PtGA of PsA disease activity (47.0% vs 10.7%; <i>P</i> < 0.001) and PsA Pain (45.5% vs 16.1%; <i>P</i> < 0.001). At W16, icotrokinra improved mNAPSI by 41.6% (vs 118.6% worsening with placebo; <i>P</i> < 0.001). Adverse event rates were similar between icotrokinra and placebo.</p><p><strong>Conclusions: </strong>Icotrokinra demonstrated early, substantial improvements in participant-reported PsA activity and PsA Pain, and nail psoriasis, with a favorable safety profile through W16 in participants with PsO+PsA.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261494526"},"PeriodicalIF":0.0,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13677984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Switching From Deucravacitinib to Tildrakizumab in Psoriasis: A 28-Week Real-World Study.","authors":"Yohei Takahashi, Teppei Hagino, Manami Yoneyama, Mizuki Shiba, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda","doi":"10.1177/24755303261497686","DOIUrl":"https://doi.org/10.1177/24755303261497686","url":null,"abstract":"<p><strong>Background: </strong>Deucravacitinib, a tyrosine kinase 2 inhibitor, has shown efficacy and tolerability in moderate-to-severe psoriasis. However, evidence on switching from deucravacitinib to an interleukin-23 inhibitor is limited.</p><p><strong>Objective: </strong>We examined outcomes after switching from deucravacitinib to the anti-interleukin-23p19 antibody tildrakizumab.</p><p><strong>Methods: </strong>We conducted a single-center retrospective study of 15 adults (aged ≥18 years) with psoriasis who showed an insufficient response to ≥16 weeks of deucravacitinib 6 mg. Insufficient response was defined as < 75% improvement of psoriasis area and severity index (PASI) from baseline, or a static physician's global assessment (sPGA) score of ≥2. After switching, patients received tildrakizumab 100 mg at weeks 0 and 4, followed by every 12 weeks. We assessed PASI, sPGA, and the dermatology life quality index (DLQI) at weeks 4, 16, and 28.</p><p><strong>Results: </strong>At week 28, the mean percent reductions from baseline were 89.0% for PASI and 77.2% for DLQI. The achievement rates of PASI 75, PASI 90, PASI 100, and sPGA 0/1 at week 28 were 88.9%, 55.6%, 44.4%, and 77.8%, respectively. The achievement rates of PASI ≤3, PASI ≤2, PASI ≤1, and DLQI 0/1 at week 28 were 88.9%, 77.8%, 55.6%, and 50.0%, respectively. Three treatment-related adverse events (AEs) occurred; eczema in 2 patients (13.3%) and arthralgia in 1 patient (6.7%).</p><p><strong>Conclusions: </strong>These preliminary findings suggest that tildrakizumab may be a treatment option for patients with an insufficient response to deucravacitinib.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261497686"},"PeriodicalIF":0.0,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13654008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).","authors":"Bruce Strober, Matthias Augustin, Yayoi Tada, Kimberly Parnell Lafferty, Yevgeniy Krol, Elizabeth Skobelev, Fowzia Ibrahim, Steven Fakharzadeh, Robert Gniadecki","doi":"10.1177/24755303261477021","DOIUrl":"https://doi.org/10.1177/24755303261477021","url":null,"abstract":"<p><strong>Background: </strong>The first phase of the Psoriasis Longitudinal Assessment and Registry (PSOLAR) provided safety, demographic, and other outcomes data from >12,000 patients (>75,000 patient-years) eligible to receive biologics for psoriasis. In 2018, PSOLAR enrollment criteria were updated to specifically include patients receiving either guselkumab or an interleukin-17 inhibitor (IL-17i).</p><p><strong>Methods: </strong>Baseline characteristics are described for patients included in PSOLAR after adoption of Protocol Amendment 6 (March 26, 2018), which updated enrollment criteria to include patients exposed to guselkumab or an IL-17i.</p><p><strong>Results: </strong>As of July 12, 2025, 3501 patients (guselkumab, n = 2213; IL-17i, n = 1288) were enrolled at sites in 17 countries. Baseline characteristics were generally balanced between the guselkumab and IL-17i cohorts. The majority of patients were male (59.9%), white (74.3%), and overweight/obese (78.5%; mean [SD] BMI = 30.2 [7.2] kg/m²). Mean (SD) age was 50.3 (13.9) years. On average, patients had longstanding psoriasis at baseline (mean [SD] duration of psoriasis = 19.0 [13.7] years; mean [SD] body surface area = 8.6% [12.7]). Most patients reported current or prior history of alcohol use (77.3%) and smoking (54.1%). Prior to enrollment, most patients (76.9%) reported exposure to ≥1 biologic. Self-reported psoriatic arthritis was less common in the guselkumab vs the IL-17i group (25.0% vs 38.1%).</p><p><strong>Conclusion: </strong>Patients with psoriasis treated with guselkumab or an IL-17i in this real-world cohort had similar baseline characteristics, although psoriatic arthritis was more common in the IL-17i group. Findings from PSOLAR may help clinicians better understand characteristics of patients who may be prescribed guselkumab or an IL-17i for psoriasis in a real-world setting.</p><p><strong>Clinicaltrialsgov identifier: </strong>NCT00508547.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261477021"},"PeriodicalIF":0.0,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148763646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphocyte-Platelet and Neutrophil-Platelet Aggregates are Associated with Dysregulated Platelet Inflammatory Pathways in Psoriasis.","authors":"Richard Ni, Isabelle L Boothman, Filipp Kazatsker, Elliot Luttrell-Williams, Kamelia Drenkova, Florencia Schlamp, Astrid Jara Pernia, Nicole L Ward, Brittany Weber, Tessa J Barrett, Jeffrey S Berger, Michael S Garshick","doi":"10.1177/24755303261464144","DOIUrl":"https://doi.org/10.1177/24755303261464144","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic immune-mediated inflammatory disease associated with heightened cardiovascular risk. Platelets are increasingly implicated in this link through their capacity to amplify vascular inflammation and interact with leukocytes. Circulating leukocyte-platelet aggregates are elevated in psoriasis, although the biological significance of these aggregates remains incompletely understood. We investigated whether increased leukocyte-platelet aggregates is associated with alterations in the platelet transcriptomic profile in psoriasis.</p><p><strong>Methods: </strong>Leukocyte-platelet aggregate levels were compared between psoriasis patients (n = 42) and healthy controls (n = 29). Psoriasis patients were stratified by the cohort median lymphocyte-platelet aggregate (LyPA) or neutrophil-platelet aggregate (NPA) levels into high vs low aggregate groups. Platelet RNA sequencing was then performed to define transcriptomic differences in high-vs low-aggregate psoriasis.</p><p><strong>Results: </strong>Psoriasis patients (mean age 46; 60% male; 81% Caucasian) had higher LyPA (<i>P</i> = 0.001) and NPA (<i>P</i> = 0.04) compared with healthy controls (mean age 42; 55% male; 69% Caucasian). Platelet RNA sequencing revealed that psoriasis patients with high LyPA or high NPA had downregulation of platelet inflammatory pathways, including interferon, tumor necrosis factor (TNF), IL-8, and IL-6 signaling.</p><p><strong>Conclusion: </strong>These findings identify inflammatory platelet transcriptomic alterations associated with elevated lymphocyte-platelet and neutrophil-platelet aggregates in psoriasis and motivate further work to define the functional consequences of leukocyte-platelet aggregates in psoriasis.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261464144"},"PeriodicalIF":0.0,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148333465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Gut Microbiome's Association in Psoriasis and Psoriatic Arthritis: A Scoping Review.","authors":"Jessica Kent, Jessica Chao, Wilson Liao, Shikha Singla","doi":"10.1177/24755303261464171","DOIUrl":"https://doi.org/10.1177/24755303261464171","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic inflammatory conditions treated with primarily immune-modulating medication. However, interest is growing in gut microbiome therapies. Studies have reported altered gut microbiota in PsO/PsA and explored probiotics and fecal microbiota transplantation (FMT) as potential therapies. This review synthesizes global studies on the microbiome's associations in PsO/PsA.</p><p><strong>Methods: </strong>We conducted a scoping literature review to understand the association between gut microbiota in PsO and PsA patients. Pubmed was used to identify 4,126 published manuscripts between 2015-2025. Thirty studies were included, encompassing 749,275 participants, with balanced gender representation and ages ranging from 18 to 76 years. These studies included 21 case-control studies, 1 case-series, 2 genome-wide analyses, 5 clinical trials, and 1 retrospective review.</p><p><strong>Results: </strong>Eighteen studies reported significant gut microbiome differences in PsO/PsA vs healthy controls. Variation in the Firmicutes/Bacteroides (F/B) ratio was of interest, with one study suggesting a low F/B ratio and five studies suggesting an elevated F/B ratio in PsO. A higher F/B ratio was linked to increased acetate production. Acetate and propionate, key short-chain fatty acids (SCFAs), were associated with modulation of the IL-23/Th17 axis in psoriasis and activation of keratinocytes. The role of therapeutics targeting the gut microbiome was explored. Ustekinumab and tofacitinib altered gut microbiome composition. Probiotic and FMT interventions showed mixed outcomes. Six of eight probiotic studies reported increased SCFA producing species and/or reduced inflammatory markers. FMT improved immune markers in mice but had no significant benefit in human trials.</p><p><strong>Conclusion: </strong>Alterations in the microbiome linked to inflammation and immune response, suggest the microbiome as a potential therapeutic target for PsO/PsA.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261464171"},"PeriodicalIF":0.0,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148333550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.","authors":"Camilla Mazzanti, Marino Paroli, Gianluca Santoboni, Olga Addimanda, Bernd Raffeiner, Alessandra Bezzi, Elisa Visalli, Eleonora Celletti, Antonella Farina, Simone Bernardi, Maddalena Larosa, Romina Andracco, Patrizia Del Medico, Aldo Biagio Colella Molica, Dilia Giuggioli, Federica Lumetti, Gilda Sandri, Marta Priora, Francesca Serale, Valeria Nucera, Francesca Ometto, Elena Bravi, Alberto Lo Gullo, Palma Scolieri, Simone Parisi, Viviana Ravagnani, Rosetta Vitetta, Antonio Marchetta, Andrea Becciolini, Claudio Angrisani, Massimiliano De Simone, Rosalba Caccavalle, Massimo Reta, Mirco Magnani, Fabio Mascella, Roberta Foti, Giorgio Amato, Francesco De Lucia, Ylenia Dal Bosco, Rosario Foti, Myriam Di Penta, Emanuela Sabatini, Pietro Del Biondo, Francesco Girelli, Dario Camellino, Gerolamo Bianchi, Natalia Mansueto, Gianluca Smerilli, Veronica Franchina, Carlo Salvarani, Aurora Ianniello, Cecilia Giampietro, Eleonora Di Donato, Daniele Santilli, Gianluca Lucchini, Eugenio Arrigoni, Ilaria Platè, Vincenzo Bruzzese, Enrico Fusaro, Maria Chiara Ditto, Davide Murgia, Guido Rovera, Alessandro Volpe, Giulio Ferrero, Giuditta Adorni, Francesco Colella Molica, Alarico Ariani","doi":"10.1177/24755303261446210","DOIUrl":"https://doi.org/10.1177/24755303261446210","url":null,"abstract":"<p><p>We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We emphasize the importance of persistence, as assessed through the Drug Retention Rate (DRR), a validated measure in observational studies of biologic therapies. The DRR reflects a complex interplay of factors, including efficacy, safety, and patient choice, making it a valuable indicator of therapeutic performance. We agree that adherence is an interesting topic, but argue that its absence does not invalidate persistence data. Our study was designed to evaluate treatment persistence, not behavioural pharmacology. We believe that our methodological rigor, real-world design, and consistency with international literature make our data a reliable reference for understanding ixekizumab persistence in routine clinical pratice.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261446210"},"PeriodicalIF":0.0,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13249605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148228767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of IL-17A Inhibitors in Patients With Moderate to Severe Psoriasis in a US Claims Data-Based Cohort Study.","authors":"Maria C Schneeweiss, Joseph F Merola, Yinzhu Jin, Richard Wyss, Priyanka Anand, Arash Mostaghimi, Sebastian Schneeweiss, Robert J Glynn","doi":"10.1177/24755303261446193","DOIUrl":"https://doi.org/10.1177/24755303261446193","url":null,"abstract":"<p><strong>Background: </strong>Safety outcomes from IL-17A inhibitors have not been fully evaluated.</p><p><strong>Objective: </strong>Compare the risk of seven safety outcomes in patients with psoriasis who started treatment with either ixekizumab or secukinumab vs other biologics to treat psoriasis.</p><p><strong>Methods: </strong>In this cohort study (Apr 2016 - Dec 2022), we used US claims data to assess the risk of infections, major adverse cardiac events (MACE), inflammatory bowel disease (IBD), malignancy, and anaphylaxis, in patients with psoriasis starting an IL-17A inhibitor vs other biologics (TNF, IL-12/23, or IL-23 inhibitors).</p><p><strong>Results: </strong>Among 4261 IL-17A inhibitors users we observed no meaningfully increased risk of MACE (RR = 0.67, 0.27-1.63), or malignancy (RR = 0.92, 0.58-1.45) vs patients initiating other biologics. After propensity score matching IL-17A inhibitors users had a 3-fold increase in the risk of oral candidiasis (RR = 3.43; 1.48-7.84), a 19% increase in the risk of outpatient infections (RR = 1.19; 1.05-1.35) and a 40% increased risk of serious infections with wide confidence intervals (RR = 1.40; 0.72-2.71). We observed a signal for an increased risk of IBD based on very few events.</p><p><strong>Conclusion: </strong>Patients with psoriasis using an IL-17A inhibitor had an increased risk of oral candidiasis and outpatient infections but no increase for MACE, anaphylaxis, or malignancy compared to other biologics.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261446193"},"PeriodicalIF":0.0,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sociodemographic Factors Associated With Diagnosed Psoriasis in U.S. Adults: Patterns and Trends From NHANES and NHIS, 2003-2024.","authors":"Moshe Schneiderman, Kristina M Derrick","doi":"10.1177/24755303261448484","DOIUrl":"https://doi.org/10.1177/24755303261448484","url":null,"abstract":"<p><strong>Objective: </strong>To quantify sociodemographic differences in the prevalence of diagnosed psoriasis and to evaluate temporal trends in its epidemiologic distribution.</p><p><strong>Methods: </strong>Data from the 2003-2006 and 2009-2014 National Health and Nutrition Examination Survey and the 2023-2024 National Health Interview Survey were analyzed. Meta-analysis was performed to determine whether age, sex, race/ethnicity, interview language, marital status, BMI, education, income, and health insurance are independently associated with odds of diagnosed psoriasis. Estimates from each survey period were tested for linear trends over time.</p><p><strong>Results: </strong>The total sample included 53,225 participants. Spanish speakers, compared to English speakers, demonstrated markedly lower prevalence of diagnosed psoriasis (pooled aOR = 0.40, 95% CI = 0.25-0.65), even after adjusting for other sociodemographic factors including race/ethnicity. Other factors independently associated with psoriasis were older age, non-Hispanic White race/ethnicity, and higher BMI (all <i>P</i> < 0.001). No temporal trends in prevalence were found in any sociodemographic subgroup.</p><p><strong>Conclusion: </strong>This analysis of national data covering an almost 25-year period indicates psoriasis has consistently been one of the most common inflammatory skin diseases with a stable sociodemographic distribution over this time. High rates of potentially undiagnosed psoriasis among vulnerable sociodemographic subgroups may be a persistent issue spanning over 2 decades. Patients with limited English proficiency may have difficulty interacting with the healthcare system, leading to undiagnosed psoriasis. Difficulty of diagnosis in patients with skin of color may also contribute. Given that psoriasis is a condition with systemic effects, including impacts on cardiovascular risk, accurate and timely diagnosis is essential to ensure appropriate clinical management.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261448484"},"PeriodicalIF":0.0,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ambient Temperature and Psoriatic Arthritis Odds Among Patients With Psoriasis: A Cross-sectional Analysis.","authors":"Michael R Nock, Stacy Ahn, Charles E Leonard, Alexis Ogdie, Jeffrey M Cohen","doi":"10.1177/24755303261446203","DOIUrl":"10.1177/24755303261446203","url":null,"abstract":"<p><strong>Background: </strong>Although there has been growing interest in better understanding risk factors for progression from psoriasis (PsO) to psoriatic arthritis (PsA), research on the role of ambient temperature in potentiating PsA risk has been limited. We sought to evaluate the association of average-annual ambient temperature exposure with prevalent PsA diagnosis among a large cohort of US adults with PsO.</p><p><strong>Methods: </strong>We studied electronic health record-data from participants with PsO, with and without an associated PsA diagnosis, who enrolled in the National Institutes of Health's All of Us Research Program between May 31, 2017, and July 1, 2022. Average-annual ambient temperature exposure data was obtained from the National Oceanic and Atmospheric Administration. Multivariable logistic regression analysis was utilized to assess the association between three-digit Zone Improvement Plan (ZIP) code-level ambient temperatures and prevalent PsA diagnosis, controlling for patient age, sex, body mass index, smoking history, race and ethnicity, income, urbanicity, and community deprivation.</p><p><strong>Results: </strong>In this cohort of 5466 patients with PsO (mean age [SD], 61.86 years [15.45 years]; 3153 females [57.7%]) and 1080 patients with both PsO and PsA (mean age [SD], 60.76 years [13.48 years]; 665 females [61.6%]), each 1°F increase in average-annual ambient temperature was associated with 2% increased odds of prevalent PsA diagnosis (adjusted odds ratio [aOR], 1.02; 95% CI, 1.01-1.03).</p><p><strong>Conclusion: </strong>Our study provides data to support further investigation of long-term, warmer ambient temperature exposure as a potential risk factor for PsA among those with PsO.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261446203"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13110246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}